About this Research Topic
Background - Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure without any identifiable pathology in the brain and with normal cerebrospinal fluid (CSF) composition. A typical patient of IIH is an obese woman of childbearing age. Headache is the most common symptom. Papilledema, or optic disc swelling is the main finding. Visual loss, which is the only serious complication, may occur either early or late in the course of the disease. OCT has shown promise for diagnosis and monitoring of patients. The etiology of IIH is still unclear. Recent evidence suggests that it is a disease of metabolic dysregulation. Classical choices of medical treatment are diuretics, particularly acetazolamide or furosemide, and encouragement of weight loss. Medical options, including 11β-Hydroxysteroid Dehydrogenase Type 1 inhibitors are on the way. Treating headaches with monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) signaling pathway is also a recent development. Optic nerve sheath fenestration (ONSF) and CSF diversion procedures are effective surgical treatment modalities. Cerebral venous sinus stenting is an emerging strategy.
Details for authors - The scope of this Research Topic is to make a review of IIH dealing mainly with recent advances in the pathophysiology, patient monitoring and treatment. Subtopics will include:
Novel advances in monitoring the disease
Current and emerging medical treatments
Surgical treatment options
Keywords: Headache, Papilledema, Diplopia, CSF Pressure, Treatment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.